News Archive
03/17/2023: Hepatitis Delta, Aisf and Simit specialists present joint and updated document
03/14/2023: Scottish Medicines Consortium accepts treatment for chronic hepatitis delta virus
01/21/2023: Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy
01/11/2023: Identifying and Screening At-Risk Patients for Hepatitis Delta Virus: A Case Report
01/03/2023: A 3-Year Course Of Bulevirtide Monotherapy May Cure HDV Infection In Cirrhotics
11/26/2022: The Delta Delta: Gaps in screening and patient assessment for hepatitis D virus infection
11/11/2022: Bulevirtide Improves Health-Related Quality of Life (Phase 3 Clinical Trial Presentation at AASLD)
10/27/2022: COVID-19 Impacts HDV Screening, Patient Outcomes
09/2022: Presentation from International HBV Meeting: Combined results from the clinical trials MYR203 and MYR301, in patients with chronic hepatitis D
09/25/2022: Replicor Inc. has updated clinical data on the compassionate use program for treating chronic HBV/HDV co-infection in cirrhotic patients
09/2022: Diagnosing and Screening for Hepatitis D Viral Infection
08/30/2022: Hepatitis Delta virus in migrants: The challenge of elimination (ANRS CO22 HEPATHER cohort)
06/2022: EASL Presentation - Peginterferon Lambda combined with Lonafarnib diminished triphasic HDV kinetic pattern seen under PEG-IFN Lambda monotherapy
06/2022: EASL Presentation - Mathematical modeling of HDV RNA kinetics suggests high peginterferon lambda efficacy in blocking viral production
06/2022: EASL Presentation - Rising Clinical and Economic Burden Among Hepatitis D Patients Who Attended Spanish Hospitals
06/2022: EASL Presentation - Provider Factors Shaping Hepatitis Delta Screening
06/2022: EASL Presentation - Hepatitis delta virus reflex testing in patients with hepatitis B dramatically improves the HDV screening cascade: 10 years of real-world experience
06/27/2022: Eiger BioPharmaceuticals Announces Results from Multiple Presentations at EASL 2022
06/27/2022: Vir Biotechnology Inc. (VIR) Announces New Clinical Data From its Broad Hepatitis B Program
06/16/2022: Review shines a light on the overlooked virus, hepatitis D
06/08/2022: Eiger BioPharmaceuticals Announces Multiple Presentations at EASL 2022
05/12/2022: Research Article Examining the Different Evolutionary Dynamics of the hepatitis B and hepatitis D virus
04/27/2022: Vir Biotechnology Unveils New Hepatitis D Clinical Program
03/23/2022: New Hepatitis D Central Resource Available from Healio
02/17/2022: Four Questions with Professor Maria Buti: Understanding Hepatitis D
02/11/2022: New Hepatitis Delta Podcast Episode: Viral Hepatitis: On the Road to Elimination
02/04/2022: Patient Perspective: Living with HBV and HDV Coinfection in Pandemic Times
01/20/2022: Hepatitis D Changing Context Global Prevalence
01/04/2022: New Slideset Updated on Don't Delay with Delta: Best Practices and Calls to Action in HDV
12/21/2021: Bulevirtide Improves Quality of Life in Chronic HDV
12/20/2021: Medical Minutes Podcasts on HDV Epidemiology and Universal Screening
12/16/2021: UN Adopts Resolution on Rare Diseases
12/13/2021: Bulevirtide Shows Real-World Efficacy Versus HDV
12/03/2021: Should We Screen All Patients with Hepatitis B for Hepatitis Delta?
12/01/2021: Hepatitis Delta Presentations from the 2021 AASLD Liver Meeting Now Available
11/19/2021: Gilead Files BLA for Bulevirtide to Treat Chronic HDV Infection
07/28/2021: Hepatitis D: Neglected Disease in the Race to Eliminate Viral Hepatitis by 2030
07/12/2021: Significant Disruptions in the International Incidence of Hepatitis Delta Virus
06/25/2021: Gilead Preps Filing for Hepatitis D Therapy Hepcludex in US
04/01/2021: Hepatitis Delta Infection Among Persons with HIV in Europe
10/7/20: Risk Factors for Delta Hepatitis in a North American Cohort: Who Should Be Screened?
9/17/20: Hepcludex Launched in Germany, France, and Austria
8/5/20: Hepcludex Approved by European Commission
2/18/20: New Insights into Hepatitis B and Hepatitis Delta Virus Entry
1/2/20: Hepatitis Delta Has Higher Health Care Cost Burden Than Hepatitis B
12/26/19: REP2139 Demonstrates Functional Cure in Both HBV, HDV
11/12/19: Eiger Announces Phase 2 LIFT Study Results During AASLD 2019
11/1/19: MYR Pharmaceuticals to Present on Myrcludex B During AASLD 2019
11/1/19: FDA Guidance to Help with Hepatitis Delta Drug Development
8/20/19: Pegylated Interferon Lambda Receives FDA Breakthrough Therapy Designation
7/29/19: Russia Plans Production of Myrcludex B
4/13/19: MYR Announces Phase 2 Myrcludex B Trial Data at The International Liver Congress 2019
4/11/19: Eiger Announces Phase 2 LIMT Hepatitis Delta Study Progress at The International Liver Congress 2019
12/18/18: Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib
12/17/18: Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib
6/4/18: Digestive Disease Week: Hepatitis Delta: The 'Forgotten Virus' is Still Here
10/23/18: MYR Pharma Announces FDA Breakthrough Therapy Designation for Myrcludex B
9/5/17: Pegylated Interferon Lambda Receives FDA Orphan Drug Designation
7/27/17: Pegylated Interferon Lambda Receives FDA Fast Track Designation
5/25/17: MYR Pharma Announces Myrcludex B PRIME Designation by the EMA
12/22/14: Lonafarnib Recieves Orphan Drug Designation by FDA and EMA